FBRX
Forte Biosciences, Inc.
Next earnings Aug 12, 2026 · consensus $-1.05 EPS
Last earnings -2.8% on 2026-05-14
$21.03
▲ +12.40%$21.03▲ +64.81%
over 1Y
L $9.45EODHDH $35.53
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+12.4%
1W+15.0%
1M-2.0%
3M-17.5%
YTD-10.9%
1Y+64.8%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 11 analysts
Buy
Conservative balance sheet (liabilities/equity 0.36x); but revenue fell -99.8% YoY.
Revenue (FY2019) $36.0K · FY2019
Forte Biosciences, Inc. shows $36.0K in FY2019 revenue (-99.8% YoY), a -192708.3% net margin, and -113.7% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$21.5M | -$13.9M | -$32.5M | -$36.6M | -$70.7M |
| Net income | -$21.7M | -$13.9M | -$31.5M | -$35.5M | -$69.4M |
| Diluted EPS | -$1.55 | -$0.80 | -$24.92 | -$12.17 | -$4.71 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$241M
EV / EBITDA—
EV / Sales6701.7
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-23.8%
FCF yield-17.5%
Quality & risk
ROIC (est.)-64.0%
Free cash flow-$51.0M
Total debt$26.2M
Net cash$50.8M
Altman Z-Score2.31 grey
Piotroski F-Score1/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+111.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- S-3/A Shelf registration (potential raise)2026-06-08
- 8-K Officer / director change2026-06-02
- S-3 Shelf registration (potential raise)2026-06-02
- 8-K Earnings results2026-05-14
- 10-Q Quarterly report2026-05-11
- DEF 14A Proxy statement2026-04-29
- 8-K Material agreement2026-04-09
- 8-K Earnings results2026-04-01
- 10-K Annual report2026-03-31
Recent filings
all on EDGAR ↗4Period ending 2026-06-162026-06-17open ↗4Period ending 2026-06-162026-06-17open ↗EFFECTFiling2026-06-10open ↗SCHEDULE 13GFiling2026-06-08open ↗S-3/AFiling2026-06-08open ↗4Period ending 2026-05-292026-06-02open ↗S-3Filing2026-06-02open ↗4Period ending 2026-05-292026-06-02open ↗4Period ending 2026-05-292026-06-02open ↗4Period ending 2026-05-292026-06-02open ↗4Period ending 2026-05-292026-06-02open ↗4Period ending 2026-05-292026-06-02open ↗
Frequently asked
- Is Forte Biosciences, Inc. (FBRX) a buy?
- FBRX currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.36x); but revenue fell -99.8% YoY.
- What is Forte Biosciences, Inc.'s quality score?
- FBRX scores 30.450980392156858/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001419041, latest 10-Q filed 2026-05-11) · EODHD · as of 6/26/2026, 7:29:01 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.